SEARCH

SEARCH BY CITATION

References

  • 1
    McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116122 .
  • 2
    Jones RJ, Lee KS, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778783.
  • 3
    McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255267.
  • 4
    Hasegawa S, Horibe K, Kawabe T et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant 1998; 22: 11911197.
  • 5
    Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 35993604.
  • 6
    Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 15011506.
  • 7
    Richardson PG, Elias AD, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737744.
  • 8
    Nimer SD, Milewicz AL, Champlin RE, Busuttil RW. Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation 1990; 49: 819821.
  • 9
    Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant 1991; 8: 421424.
  • 10
    Dowlati A, Honore P, Damas P et al. Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation. Transplantation 1995; 60: 106109.
  • 11
    Schlitt HJ, Tischler HJ, Ringe B et al. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation – clinical and immunological considerations. Bone Marrow Transplant 1995; 16: 473478.
  • 12
    Hagglund H, Ringden O, Ericzon BG et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996; 62: 10761080.
  • 13
    Bunin N, Leahey A, Dunn S. Related donor liver transplant for veno-occlusive disease following T-depleted unrelated donor bone marrow transplantation. Transplantation 1996; 61: 664666.
  • 14
    Norris S, Crosbie O, McEntee G et al. Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation. Transplantation 1997; 63: 15211524.
  • 15
    Rosen HR, Martin P, Schiller GJ et al. Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver. Liver Transpl Surg 1996; 2: 225232.
  • 16
    Salat C, Holler E, Wolf C et al. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation. Bone Marrow Transplant 1997; 19: 487490.
  • 17
    Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 11711181.
  • 18
    Ohashi K, Tanabe J, Watanabe R et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 3238.
  • 19
    Or R, Nagler A, Shpilberg O et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61: 10671077.
  • 20
    Gluckman E, Jolivet I, Scrobohaci ML et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation [see comments]. Br J Haematol 1990; 74: 277281.
  • 21
    Morris JD, Harris RE, Hashmi R et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871878.
  • 22
    Behm FG, Raimondi SC, Frestedt JL et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996; 87: 2870287.